As previously reported, it has been verified that after transferrin modification, Tf-CTM exhibited enhanced anti-cervical cancer treatment (Qu et al., 2015, 2017; Chen et al., 2018; Qu et al., 2018). The gene discussed is HSF4; the disease is cervical cancer.